

# Fetal hemoglobin may provide a useful dynamic biomarker during hypomethylating agent therapy of patients with myelodysplastic syndrome and acute myeloid leukemia



40

Patients with myelodysplastic syndrome (MDS, n=15) and acute myeloid leukemia (AML, n=25)



Decitabine treatment




High-performance liquid chromatography

PRE-TREATMENT

COURSE 1

COURSE 2



Groups A 11 HbF > upper limit of normal (ULN)

B 12 HbF within the normal range

C 13 HbF remained > ULN

D 3 HbF dropped to normal levels

Median HbF 0.8%

1.1%

Median fold-change of HbF

1.67 (p=0.088)



MDS

Group C (n=9)

Group D (n=6)

OS	22.9 months	7.3 months	HR 0.21 [95% CI 0.05-0.87], p=0.03
PFS	7.7 months	2.4 months	HR 0.32 [95% CI 0.10-1.10], p=0.07
Median AMLFS	13.1 months	7.6 months	HR 0.42 [95% CI 0.13-1.38], p=0.15



AML

Group C (n=9)

Group D (n=8)

OS	17.3 months	11.6 months	n.s.
----	-------------	-------------	------